Truist Financial Cuts Incyte (NASDAQ:INCY) Price Target to $72.00
Incyte (NASDAQ:INCY – Free Report) had its price target reduced by Truist Financial from $74.00 to $72.00 in a report issued on Tuesday,Benzinga reports. They currently have a hold rating on the ...
Zacks Investment Research on MSN18 小时
INCY Stock Down on Disappointing Skin Disease Study Data
Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral ...
Charles Schwab Investment Management Inc. Increases Stock Position in Protagonist ...
Charles Schwab Investment Management Inc. lifted its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free ...